Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 626 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL November 10, 2021 Dog Finds Woman’s Lost Wedding Ring At The Beach August 18, 2021 Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer May 25, 2018 Cancer Survivor And His Organ Donor Run NYC Marathon Together To... November 7, 2021 Load more HOT NEWS Targeting the Accomplice: A Potential Treatment Approach for Rhabdomyosarcoma FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for... A tribute to Professor Gordon McVie Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or...
